查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1924720

口服多發性硬化症治療藥物市場（依分子、藥物類別、適應症、治療階段、劑型及通路）——2026-2032年全球預測

Oral Medications for Multiple Sclerosis Market by Molecule, Drug Class, Indication, Line Of Therapy, Dosage Form, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，多發性硬化症口服藥物市場價值將達到 63.7 億美元，到 2026 年將成長至 67.6 億美元，到 2032 年將達到 104.4 億美元，年複合成長率為 7.31%。

關鍵市場統計數據
基準年 2025 63.7億美元
預計年份：2026年 67.6億美元
預測年份 2032 104.4億美元
複合年成長率 (%) 7.31%

針對不斷發展的口服多發性硬化症治療生態系統，制定一項策略性方法，將臨床差異化與商業性和市場准入優先事項結合。

由於治療方案組合、監管環境和治療路徑的不斷演變，口服多發性硬化症治療領域正經歷重大重組。本概要旨在為高階主管、臨床開發負責人、支付方負責人和商業團隊提供結構化的指導，幫助他們簡潔全面地了解當前趨勢和即將到來的轉折點。重點在於口服緩解疾病治療藥物（DMARDs），這些藥物具有不同的作用機制，會對處方模式、病患依從性以及醫療照護目錄談判產生影響。

基於機制的差異化、加強監管以及循證商業模式將如何重塑口服多發性硬化症治療藥物的研發路徑和市場動態

口服多發性硬化症治療領域正經歷一場變革，這場變革正在重新定義治療方法的研發、處方以及在醫療保健系統中的整合方式。基於機制的差異化是商業策略的核心。富馬酸酯類、鞘氨醇-1-磷酸受體調變器和二氫乳清酸去氫酶抑制劑各自具有不同的療效和安全性權衡，臨床醫生可以利用這些權衡，根據疾病活動度、合併症情況和患者意願來制定個人化治療方案。這種分子層次和類別層面的多樣性凸顯了頭對頭資料、長期安全性監測和真實世界證據對於指導治療順序決策的重要性。

2025年前對口服多發性硬化症療法的影響：在美國關稅變化和全球採購壓力下管理供應鏈韌性和商業性連續性

2025年美國即將生效的新關稅政策和貿易趨勢將進一步增加口服多發性硬化症治療藥物生產商和相關人員的複雜性。關稅調整將影響原料藥、輔料、包裝材料和成品的到岸成本，而這些都依賴全球生產和採購網路。因此，企業將更加重視加強供應鏈韌性、實現供應商多元化以及最佳化服務交付成本，以在確保可預測的供應的同時保護利潤率。

將分子特徵、治療領域、適應症和分銷管道趨勢聯繫起來的細分市場洞察，為證據、准入和商業化策略提供資訊。

一項涵蓋分子特徵、治療領域、臨床適應症、治療順序、劑型和分銷管道的詳細細分分析揭示了關鍵機會和限制因素。以分子為中心觀點，可以區分出富馬酸二甲酯、富馬酸二甲酯、Fingolimod、富馬酸單甲酯、ozanimod、Ponesimod、Siponimod和特立氟胺等藥物。每種藥物都具有獨特的特徵，這些特徵會影響耐受性、監測需求和患者偏好。這些個人化的分子特徵會影響處方醫師的選擇，也是療效比較評估和藥物目錄協商的核心基礎。

美洲、歐洲、中東和非洲以及亞太地區的市場准入和支付方趨勢將影響口服多發性硬化症藥物的市場上市順序和長期應用。

區域趨勢對於理解臨床實踐、監管預期和支付方行為如何相互交織，共同影響口服多發性硬化症藥物的可及性至關重要。在美洲，人口結構的變化、支付方影響力的集中以及已建立的專科藥房網路，使得處方集談判和基於療效的安排成為關鍵考慮因素。在該地區運營的製藥企業必須設計完善的市場進入材料，投資收集真實世界證據，並製定有針對性的患者援助計劃，以減少處方和配藥過程中的摩擦。

製造商、生物技術創新者和通路夥伴如何協調生命週期、商業和營運策略，以確保口服多發性硬化症治療藥物的可近性和規模化應用？

在口服多發性硬化症領域，各公司採取的策略體現了多元化的方法，涵蓋分子創新、生命週期管理、商業性執行和生態系統夥伴關係。創新先行者專注於透過擴展安全性資料庫、最佳化適應症和產生比較療效證據來實現差異化。此外，他們還投資於患者支援基礎設施、數位依從性解決方案和集中式報銷團隊，以應對複雜的支付方要求並保持處方醫生的信心。

產業領導者在口服多發性硬化症療法商業化過程中整合證據、供應鏈彈性、病患支持和適應性合約的實用策略重點

為了在口腔多發性硬化症領域創造永續價值，產業領導者應採取多管齊下的策略，整合臨床差異化、實證醫學證據和商業性彈性。首先，應優先制定嚴謹的循證方案，包括盡可能開展頭對頭試驗、建立可靠的真實世界證據項目以及建立長期安全性註冊登記系統，以直接解決支付方的擔憂和臨床醫生的決策標準。這些實證基礎的設計應同時支持國家衛生技術評估和區域支付方對話。

嚴謹的混合方法調查方法，融合了臨床文獻回顧、相關人員訪談和三角驗證證據，檢驗有關口腔多發性硬化症的研究結果。

本分析的調查方法融合了第一手和第二手研究，並採用嚴謹的三角驗證法，以確保分析的穩健性和實用性。第二手研究包括對同儕審查的臨床文獻、監管申報文件、處方指南和公共政策聲明進行全面審查，以確定口服多發性硬化症藥物的臨床和監管背景。為了完善這項基礎，本研究也整合了治療路徑文獻和醫療服務報告，以繪製通路和獲取管道圖。

將臨床差異化、營運韌性和客製化市場進入相結合，為口腔多發性硬化症相關人員提供可操作的結論，實現高水準的整合。

總之，口服多發性硬化症藥物的市場環境日益複雜，同時也為建立策略優勢指明了方向。富馬酸鹽、鞘氨醇受體調變器和二氫乳清酸去氫酶抑制劑等藥物的分子多樣性豐富了治療選擇，但也凸顯了比較證據和差異化價值提案的必要性。 2025年的關稅和供應鏈考量為市場營運增添了新的維度，迫使製造商比以往任何時候都更加緊密地整合成本、韌性和市場准入策略。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 分子層面的口服多發性硬化症治療市場

  • 富馬酸二甲酯
  • 富馬酸二甲酯
  • Fingolimod
  • 富馬酸單甲酯
  • ozanimod
  • Ponesimod
  • Siponimod
  • Teriflunomide

9. 依藥物類別分類的口服多發性硬化症藥物市場

  • 二氫乳清酸去氫酶抑制劑
  • 富馬酸鹽
    • 富馬酸二甲酯
    • 富馬酸二甲酯
    • 富馬酸單甲酯
  • 鞘氨醇-1-磷酸受體調變器
    • Fingolimod
    • ozanimod
    • Ponesimod
    • Siponimod

第10章 依適應症分類的口服多發性硬化症治療市場

  • 臨床孤立症候群
  • 復發型多發性硬化症
  • 次發漸進型多發性硬化症（活動期）

第11章 依治療階段分類的口服多發性硬化症藥物市場

  • 主要治療
  • 後續治療
  • 二級治療

第12章 依劑型分類的口服多發性硬化症治療市場

  • 膠囊
  • 藥片

13. 多發性硬化症口服治療藥物市場（依分銷管道分類）

  • 醫院藥房
  • 零售藥房
  • 專科藥房

14. 各地區口服多發性硬化症藥物市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 多發性硬化症口服治療藥物市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

16. 各國口服多發性硬化症藥物市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

17. 美國用於治療多發性硬化症的口服藥物市場

第18章：中國多發性硬化症口服藥物市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Acorda Therapeutics, Inc.
  • Bayer AG
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • Clene Nanomedicine, Inc.
  • Eisai Co., Ltd.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Immensa Biotherapeutics, Inc.
  • Immunic, Inc.
  • Janssen Pharmaceuticals, Inc.
  • Merck KGaA
  • Mitsubishi Tanabe Pharma Corporation
  • Novartis AG
  • Oryzon Genomics, SA
  • Pfizer Inc.
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
Product Code: MRR-7A380DA7C450

The Oral Medications for Multiple Sclerosis Market was valued at USD 6.37 billion in 2025 and is projected to grow to USD 6.76 billion in 2026, with a CAGR of 7.31%, reaching USD 10.44 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.37 billion
Estimated Year [2026] USD 6.76 billion
Forecast Year [2032] USD 10.44 billion
CAGR (%) 7.31%

A strategic orientation to the evolving oral therapy ecosystem for multiple sclerosis that aligns clinical differentiation with commercial and access priorities

The oral multiple sclerosis landscape is undergoing a significant recalibration driven by evolving therapeutic portfolios, regulatory trajectories, and shifting care pathways. This summary provides a structured orientation for senior executives, clinical development leads, payer strategists, and commercial teams who require a concise yet comprehensive synthesis of current dynamics and near-term inflection points. The focus is on oral disease-modifying therapies, where molecules with diverse mechanisms of action are influencing prescribing patterns, adherence outcomes, and formulary negotiations.

In recent years, the proliferation of oral options has altered the balance between efficacy, safety, convenience, and cost considerations, prompting clinicians and health systems to rethink traditional routing through infusion or injectable channels. As a result, stakeholders must understand how molecular differentiation, class-specific safety profiles, and patient-centric attributes such as dosing regimens and tolerability are shaping first-line adoption and subsequent sequencing strategies. This introduction sets the scene for deeper analysis of transformative shifts, tariff-driven cost pressures, segmentation-level implications, regional patterns, company strategies, and recommended actions that follow in the full executive summary.

By synthesizing clinical, regulatory, commercial, and distribution perspectives, this document underscores the multifaceted pressures and opportunities that oral multiple sclerosis therapies present. It aims to equip decision-makers with the contextual intelligence needed to prioritize investments, refine value propositions, and align cross-functional plans for optimized patient access and sustained competitive advantage.

How mechanism-led differentiation, regulatory vigilance, and evidence-driven commercial models are reshaping oral multiple sclerosis treatment pathways and market dynamics

The oral multiple sclerosis treatment environment is in the midst of transformative shifts that are reframing how therapies are developed, prescribed, and integrated into health systems. Mechanism-driven differentiation is now a central commercial lever: fumarates, sphingosine 1 phosphate receptor modulators, and dihydroorotate dehydrogenase inhibitors each convey distinct efficacy and safety trade-offs that clinicians use to tailor therapy to disease activity, comorbidity profiles, and patient preferences. This molecular and class diversity has increased the importance of head-to-head data, long-term safety surveillance, and real-world evidence to guide sequencing decisions.

Concurrently, regulatory pathways and labeling updates have emphasized safety monitoring and post-authorization commitments, prompting manufacturers to invest more heavily in pharmacovigilance and patient support services. These developments are catalyzing partnerships between commercial, medical affairs, and market access teams to align evidence-generation plans with reimbursement needs. Moreover, advances in patient-centric care models, digital adherence tools, and decentralized dispensing are enhancing uptake of oral therapies by reducing barriers associated with clinic visits and infusion center capacity constraints.

On the payer and provider side, value-based contracting and outcomes-based agreements are gaining traction as mechanisms to manage uncertainty around long-term effects and to align price with observed clinical benefit. Pharmaceutical manufacturers are responding with tailored pricing strategies and targeted education for prescribers and payers that highlight differentiating attributes such as tolerability, switching pathways, and monitoring requirements. Taken together, these shifts are creating a more dynamic marketplace where clinical nuance, evidence strategy, and commercial agile capabilities determine which therapies capture durable adoption.

Managing supply chain resilience and commercial continuity amid United States tariff fluctuations and global sourcing pressures affecting oral multiple sclerosis therapies in 2025

Emerging tariff policies and trade dynamics in the United States during 2025 introduce an additional layer of complexity for manufacturers and supply chain stakeholders in the oral multiple sclerosis arena. Tariff adjustments affect landed costs of active pharmaceutical ingredients, excipients, packaging materials, and finished products that rely on global manufacturing and sourcing networks. The result is an increased emphasis on supply chain resilience, supplier diversification, and cost-to-serve optimization to maintain predictable access while protecting margins.

Manufacturers with vertically integrated supply chains or local production capabilities are positioned to mitigate some tariff-driven cost exposure, while those dependent on cross-border sourcing must evaluate hedging strategies, renegotiation of supplier terms, and potential repricing measures. These pressures are likely to accelerate near-shoring and the reallocation of manufacturing capacity to jurisdictions with favorable trade regimes and stable logistics infrastructure. In parallel, commercial teams will need to engage payers proactively to contextualize any price adjustments and to explore risk-sharing constructs that protect patient access.

From a clinical operations standpoint, tariff-induced cost volatility underscores the importance of maintaining unfettered access to critical therapies through robust inventory planning and alternative distribution channels. Specialty pharmacies and hospital procurement organizations will play pivotal roles in buffering short-term supply disruptions, while manufacturers will need transparent communication protocols to preserve trust with providers and patients. Ultimately, managing the cumulative impact of tariffs in 2025 requires integrated cross-functional planning that balances commercial strategy, regulatory compliance, and operational agility to safeguard continuity of care.

Segment-level intelligence connecting molecule attributes, therapeutic classes, indications, and channel dynamics to inform evidence, access, and commercialization tactics

A granular segmentation lens reveals critical opportunities and constraints across molecule-level attributes, therapeutic classes, clinical indications, treatment sequencing, dosage forms, and distribution channels. The molecule-focused perspective distinguishes agents such as Dimethyl Fumarate, Diroximel Fumarate, Fingolimod, Monomethyl Fumarate, Ozanimod, Ponesimod, Siponimod, and Teriflunomide, each presenting unique profiles that influence tolerability, monitoring needs, and patient preference. These individual molecule characteristics inform prescriber choice and are core inputs for comparative effectiveness assessments and formulary negotiations.

At the drug-class level, the market divides into dihydroorotate dehydrogenase inhibitors, fumarates, and sphingosine 1 phosphate receptor modulators. The dihydroorotate dehydrogenase inhibitor class is exemplified by Teriflunomide, a once-daily oral agent with a distinct safety monitoring regimen. The fumarates, which include Dimethyl Fumarate, Diroximel Fumarate, and Monomethyl Fumarate, are often evaluated for their shared efficacy signals as well as differences in gastrointestinal tolerability and tolerability management strategies. The sphingosine 1 phosphate receptor modulators-Fingolimod, Ozanimod, Ponesimod, and Siponimod-are differentiated by selectivity, cardiac monitoring requirements, and pharmacokinetic profiles that influence initiation protocols and switching pathways.

Clinical indication segmentation spans clinically isolated syndrome, relapsing remitting multiple sclerosis, and secondary progressive multiple sclerosis active. These indication strata drive therapeutic intent, with early disease stages placing a premium on relapse reduction and long-term disability prevention, while active secondary progressive disease elevates the importance of neuroprotective effect and disability progression endpoints. Line-of-therapy distinctions between first line, second line, and later line use affect payer positioning and patient access pathways. Dosage form considerations-capsule versus tablet-further influence adherence and manufacturing decisions, while distribution channel segmentation across hospital pharmacy, retail pharmacy, and specialty pharmacy impacts logistics, patient support, and reimbursement workflows. Integrating these segmentation layers yields actionable insights for positioning, evidence generation, and channel-centric commercialization.

Regional access and payer dynamics across Americas, Europe Middle East & Africa, and Asia-Pacific that determine launch sequencing and long-term uptake for oral therapies

Regional dynamics are essential to understanding how clinical practice, regulatory expectations, and payer behavior converge to shape access for oral multiple sclerosis therapies. In the Americas, demographic shifts, concentrated payer influence, and established specialty pharmacy networks create an environment where formulary negotiations and outcomes-based arrangements are prominent considerations. Manufacturers operating in this region must design robust market access dossiers, invest in real-world evidence capture, and deploy targeted patient support programs to reduce friction at the point of prescribing and dispensing.

The Europe, Middle East & Africa region presents a heterogeneous regulatory and payer landscape where centralized and national-level decision-making can produce variable timelines for reimbursement and differing requirements for cost-effectiveness evidence. Health technology assessment bodies and national formularies often emphasize long-term comparative effectiveness and budget impact, necessitating tailored evidence packages and pricing approaches that reflect country-specific constraints and value frameworks. In many EMEA markets, hospital tendering and centralized procurement further influence uptake trajectories, prompting manufacturers to calibrate contracting and supply strategies accordingly.

Across the Asia-Pacific region, rapid adoption of oral therapies is shaped by diverse healthcare infrastructures, variable reimbursement capacity, and increasing investment in specialty care. Local manufacturing capabilities, government-driven price controls, and evolving regulatory pathways shape launch sequencing decisions. Success in this region frequently depends on localized clinical engagement, adaptive pricing models, and partnerships with regional distributors and specialty pharmacies to ensure sustainable access and scale.

How manufacturers, biotech innovators, and channel partners are aligning lifecycle, commercial, and operational strategies to secure access and scale for oral multiple sclerosis agents

Company-level strategies in the oral multiple sclerosis space reflect a spectrum of approaches spanning molecule innovation, lifecycle management, commercial execution, and ecosystem partnerships. Innovative originators have concentrated efforts on differentiating through expanded safety databases, label optimization, and the generation of comparative effectiveness evidence. These activities are complemented by investments in patient support infrastructure, digital adherence solutions, and centralized reimbursement teams to navigate complex payer requirements and to preserve prescriber confidence.

Emerging biotechnology firms and specialty players are leveraging nimble development programs and targeted indications to enter niches where unmet needs persist, often pursuing partnerships with larger organizations to scale commercialization and distribution. Concurrently, contract manufacturers and generic entrants are influencing pricing dynamics, especially when patent cliffs or exclusivity expirations create opportunities for lower-cost alternatives. Across the competitive landscape, strategic collaborations-for example, co-promotion, distribution agreements, and evidence-sharing compacts-are increasingly common as companies seek to align capabilities and mitigate market access risk.

Manufacturers are also prioritizing operational excellence in manufacturing robustness, serialization, and supply chain transparency to meet regulatory and payer expectations. Developing compelling value narratives that connect clinical differentiators to patient-centric outcomes, adherence benefits, and health-economic impacts will remain central to winning formulary positions and fostering durable adoption in a crowded oral therapy marketplace.

Actionable strategic priorities for industry leaders to align evidence, supply resilience, patient support, and adaptive contracting in oral multiple sclerosis commercialization

Industry leaders should adopt a multi-dimensional playbook that aligns clinical differentiation, evidence generation, and commercial agility to capture durable value in the oral multiple sclerosis environment. First, prioritize a precision evidence plan that includes head-to-head comparisons where feasible, robust real-world evidence programs, and long-term safety registries that directly address payer concerns and clinician decision-making criteria. This evidence base should be designed to support both national health technology assessments and localized payer dialogues.

Second, invest in supply chain redundancy and manufacturing flexibility to mitigate tariff and geopolitical risks. Options such as dual-sourcing of critical ingredients, selective near-shoring, and strategic buffer inventory at regional hubs can preserve continuity of access and guard against sudden cost shocks. Third, develop differentiated patient support and adherence programs that are integrated with specialty pharmacy partners and that use digital tools to improve persistence and outcomes; these programs are tangible levers for payers when assessing real-world value.

Fourth, deploy adaptive pricing and contracting mechanisms, including outcomes-based agreements where appropriate, to align reimbursement with demonstrated clinical impact and to facilitate entry into constrained payer markets. Finally, foster cross-functional alignment between medical affairs, market access, commercial, and supply teams to ensure that evidence, pricing, and distribution strategies are cohesive and rapidly executable. Taken together, these actions will enable industry leaders to navigate complexity while accelerating patient access and sustaining competitive advantage.

A rigorous mixed-methods research framework blending clinical literature review, stakeholder interviews, and triangulated evidence to validate oral multiple sclerosis insights

The research methodology underpinning this analysis blends primary and secondary research approaches with rigorous triangulation to ensure analytical robustness and practical relevance. Secondary research included comprehensive review of peer-reviewed clinical literature, regulatory filings, prescribing guidelines, and public policy announcements to establish the clinical and regulatory context for oral multiple sclerosis therapies. This foundation was complemented by synthesis of treatment pathway literature and healthcare delivery reports to map distribution and access channels.

Primary research consisted of structured interviews and targeted consultations with a cross-section of stakeholders, including neurologists with MS expertise, formulary decision-makers, hospital pharmacists, specialty pharmacy leads, and payer representatives. These engagements provided qualitative insights into prescribing rationales, reimbursement drivers, and operational constraints that shape real-world adoption. Data from these primary sources were cross-checked against secondary evidence and anonymized aggregated claims where permissible to validate patterns and identify divergences between trial-based expectations and clinical practice.

Analytical processes emphasized triangulation across data streams, sensitivity checks for tariff and supply chain scenarios, and segmentation validation informed by molecule, class, indication, line of therapy, dosage form, and distribution channel lenses. Limitations are acknowledged where data gaps exist, particularly in rapidly evolving regulatory domains or nascent real-world evidence for newer agents. Wherever possible, uncertainty was reduced through iterative expert review and scenario analysis to present a balanced and actionable account for decision-makers.

High-level synthesis linking clinical differentiation, operational resilience, and tailored market access to actionable conclusions for oral multiple sclerosis stakeholders

In summary, the oral multiple sclerosis landscape presents both heightened complexity and clear avenues for strategic advantage. Molecular diversity across agents such as fumarates, sphingosine receptor modulators, and dihydroorotate dehydrogenase inhibitors has enriched therapeutic choice but increased the demand for comparative evidence and differentiated value communication. Tariff and supply chain considerations in 2025 add an operational dimension that compels manufacturers to integrate cost, resilience, and access strategies more tightly than before.

Regional variations in regulatory rigor, payer structures, and distribution architectures mean that global strategies must be adapted for local execution, with focused investments in evidence packages that meet specific jurisdictional requirements. Company strategies that combine robust clinical evidence, agile manufacturing and supply, patient-centered support, and creative contracting will be best positioned to secure formulary placement and clinician preference. The overarching conclusion is that success in this category will rely less on a single promotional lever and more on the ability to synchronize clinical, operational, and commercial functions around demonstrable patient and payer value.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Oral Medications for Multiple Sclerosis Market, by Molecule

  • 8.1. Dimethyl Fumarate
  • 8.2. Diroximel Fumarate
  • 8.3. Fingolimod
  • 8.4. Monomethyl Fumarate
  • 8.5. Ozanimod
  • 8.6. Ponesimod
  • 8.7. Siponimod
  • 8.8. Teriflunomide

9. Oral Medications for Multiple Sclerosis Market, by Drug Class

  • 9.1. Dihydroorotate Dehydrogenase Inhibitors
  • 9.2. Fumarates
    • 9.2.1. Dimethyl Fumarate
    • 9.2.2. Diroximel Fumarate
    • 9.2.3. Monomethyl Fumarate
  • 9.3. Sphingosine 1 Phosphate Receptor Modulators
    • 9.3.1. Fingolimod
    • 9.3.2. Ozanimod
    • 9.3.3. Ponesimod
    • 9.3.4. Siponimod

10. Oral Medications for Multiple Sclerosis Market, by Indication

  • 10.1. Clinically Isolated Syndrome
  • 10.2. Relapsing Remitting Multiple Sclerosis
  • 10.3. Secondary Progressive Multiple Sclerosis Active

11. Oral Medications for Multiple Sclerosis Market, by Line Of Therapy

  • 11.1. First Line
  • 11.2. Later Line
  • 11.3. Second Line

12. Oral Medications for Multiple Sclerosis Market, by Dosage Form

  • 12.1. Capsule
  • 12.2. Tablet

13. Oral Medications for Multiple Sclerosis Market, by Distribution Channel

  • 13.1. Hospital Pharmacy
  • 13.2. Retail Pharmacy
  • 13.3. Specialty Pharmacy

14. Oral Medications for Multiple Sclerosis Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Oral Medications for Multiple Sclerosis Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Oral Medications for Multiple Sclerosis Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Oral Medications for Multiple Sclerosis Market

18. China Oral Medications for Multiple Sclerosis Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. AbbVie Inc.
  • 19.6. Acorda Therapeutics, Inc.
  • 19.7. Bayer AG
  • 19.8. Biogen Inc.
  • 19.9. Bristol-Myers Squibb Company
  • 19.10. Clene Nanomedicine, Inc.
  • 19.11. Eisai Co., Ltd.
  • 19.12. F. Hoffmann-La Roche Ltd.
  • 19.13. GlaxoSmithKline plc
  • 19.14. Immensa Biotherapeutics, Inc.
  • 19.15. Immunic, Inc.
  • 19.16. Janssen Pharmaceuticals, Inc.
  • 19.17. Merck KGaA
  • 19.18. Mitsubishi Tanabe Pharma Corporation
  • 19.19. Novartis AG
  • 19.20. Oryzon Genomics, S.A.
  • 19.21. Pfizer Inc.
  • 19.22. Sanofi
  • 19.23. Teva Pharmaceutical Industries Ltd.
  • 19.24. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIMETHYL FUMARATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIMETHYL FUMARATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIMETHYL FUMARATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIROXIMEL FUMARATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIROXIMEL FUMARATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIROXIMEL FUMARATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FINGOLIMOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FINGOLIMOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FINGOLIMOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MONOMETHYL FUMARATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MONOMETHYL FUMARATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MONOMETHYL FUMARATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY OZANIMOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY OZANIMOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY OZANIMOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY PONESIMOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY PONESIMOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY PONESIMOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SIPONIMOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SIPONIMOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SIPONIMOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY TERIFLUNOMIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY TERIFLUNOMIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY TERIFLUNOMIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIHYDROOROTATE DEHYDROGENASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIHYDROOROTATE DEHYDROGENASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIHYDROOROTATE DEHYDROGENASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIMETHYL FUMARATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIMETHYL FUMARATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIMETHYL FUMARATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIROXIMEL FUMARATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIROXIMEL FUMARATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DIROXIMEL FUMARATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MONOMETHYL FUMARATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MONOMETHYL FUMARATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MONOMETHYL FUMARATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FINGOLIMOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FINGOLIMOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FINGOLIMOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY OZANIMOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY OZANIMOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY OZANIMOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY PONESIMOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY PONESIMOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY PONESIMOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SIPONIMOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SIPONIMOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SIPONIMOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY CLINICALLY ISOLATED SYNDROME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY CLINICALLY ISOLATED SYNDROME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY CLINICALLY ISOLATED SYNDROME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY RELAPSING REMITTING MULTIPLE SCLEROSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY RELAPSING REMITTING MULTIPLE SCLEROSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY RELAPSING REMITTING MULTIPLE SCLEROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS ACTIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS ACTIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS ACTIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LATER LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LATER LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LATER LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPECIALTY PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPECIALTY PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 180. GCC ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. GCC ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 182. GCC ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 183. GCC ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2018-2032 (USD MILLION)
  • TABLE 184. GCC ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 185. GCC ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 186. GCC ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 187. GCC ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 188. GCC ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 207. G7 ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. G7 ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 209. G7 ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 210. G7 ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2018-2032 (USD MILLION)
  • TABLE 211. G7 ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 212. G7 ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 213. G7 ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 214. G7 ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 215. G7 ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 216. NATO ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. NATO ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 218. NATO ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 219. NATO ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2018-2032 (USD MILLION)
  • TABLE 220. NATO ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 221. NATO ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 222. NATO ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 223. NATO ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 224. NATO ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 225. GLOBAL ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED STATES ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED STATES ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 235. CHINA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 236. CHINA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 237. CHINA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 238. CHINA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATES, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 240. CHINA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA ORAL MEDICATIONS FOR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)